PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION28 March 2024, 08:00 a.m. CET
alfapump® – PMA1 submitted to US FDA and accepted for substantive review, extensive feedback...
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION23 January 2024, 07:00 am CET
DSMBi rates DSR 2.0 as safe following review of data from non-randomized cohort
Data from...
REGULATED INFORMATION – INSIDE INFORMATION
Pending FDA approval, alfapump could become the first active implantable medical device in the US for treating liver ascites
Ghent,...
No dose limiting toxicities were reported in the first cohort of ultra-high concentration of nitric oxide administered at 25,000 parts per million (PPM)
Phase 1...
MINNEAPOLIS, Nov. 29, 2023 /PRNewswire/ -- ShiraTronics, Inc., a pioneering medical device company, today announced the initiation of its groundbreaking RELIEV-CM pilot study in...
The U.S. Patent Office issued the following 225 patents to persons and businesses in Indiana in September 2023:
Patent Number
Patent Title
US 11766015 B1
Maize hybrid X13R074
US...
Firestein, G. S. Evolving concepts of rheumatoid arthritis. Nature 423, 356–361 (2003).Article CAS Google Scholar McInnes, I. B. & Schett, G. The pathogenesis...
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION19 October 2023, 07:00 am CEST One-year alfapump data from POSEIDON shows safety and strong efficacy profile is...
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION18 October 2023, 07:00 am CEST First two US patients from non-randomized cohort successfully treated with DSR 2.0...
September 29, 2023 South San Francisco, CA – The California Institute for Regenerative Medicine (CIRM), the world’s largest institution dedicated to regenerative medicine,...
